Form 4: Celldex Former Officer Sells Shares After Option Exercise

Richard M. Wright, a former officer of Celldex Therapeutics, Inc., executed a series of option exercises and subsequent share sales on November 13, 2025.

Summary

• Richard M. Wright, a former officer of Celldex Therapeutics, Inc. (CLDX), reported transactions on November 13, 2025.
• Wright exercised incentive stock options to acquire a total of 49,298 shares of common stock.
• The options were exercised at prices of $9.0165 for 6,876 shares, $10.38 for 26,672 shares, and $22.48 for 15,750 shares.
• Immediately following the exercises, Wright sold all 49,298 acquired shares at a weighted average price of $24.0005 per share.
• The sale prices for the disposed shares ranged from $24.00 to $24.05 per share.
• After these transactions, Wright's direct beneficial ownership of Celldex common stock is 20,833 shares.
• The options exercised were fully vested as of June 13, 2022, and June 18, 2024, for the first two tranches, while the third tranche began vesting on June 16, 2023, and continues quarterly over the subsequent 12 quarters.

Sentiment

Score: 5

Explanation: The filing is a routine report of an insider's equity transactions, specifically a sell-to-cover or cashless exercise. It reflects a former officer monetizing vested options, which is a neutral event for the company's operational performance. The sale itself is not inherently positive or negative for the company's prospects, but rather a personal financial decision.

Positives

• The former officer realized a profit by exercising options at lower prices and selling shares at a higher market price.
• The transactions demonstrate the value of the company's stock options as a form of compensation for former employees.

Negatives

• The sale of shares by a former officer, even if routine, could be perceived by some investors as a lack of long-term confidence, although it is a common practice for option exercises.
• The transactions did not result in an increase in the former officer's direct beneficial ownership of common stock.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The filing does not contain direct quotes or paraphrased statements from company management, as it is a report of an individual's transactions.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. Such transactions are common for former executives managing their equity compensation.

Management Changes

Stakeholder Impact

• Shareholders: The sale of shares by a former officer could be interpreted in various ways, from a routine financial decision to a signal of reduced confidence, potentially leading to minor short-term sentiment shifts.
• Employees: No direct impact on current employees is indicated.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction where a former officer exercised vested stock options and subsequently sold the acquired shares. This is a common practice for monetizing equity compensation and does not inherently signal a change in the company's fundamental prospects or a lack of confidence. The transaction is largely neutral from an investment perspective, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Celldex Therapeutics, CLDX, Form 4, Insider Transaction, Stock Options, Share Sale, Equity Compensation, Richard M. Wright